March 30th 2023
ISB 1442, which received orphan drug designation from the FDA, is currently under investigation in a first-in-human phase 1/2 trial as a treatment for patients with relapsed/refractory multiple myeloma.
Clinical Interchange™: Improving Outcomes and Overcoming Barriers to Equitable Care in African American Patients With Multiple Myeloma
View More
From Trials to the Real World: Assessing the Role of Allogeneic Transplant and JAK Inhibitors as Treatment Paradigms Evolve in Myelofibrosis
View More
Medical Crossfire®: How Does the Evidence Inform Your RCC Sequence? The Experts Share Clinical Perspectives
View More
Oncology On-Call®: The Experts’ Take on How Sea Changes in GvHD Prophylaxis and Management Can Be Practically Implemented in Your Clinic
View More
Community Practice Connections™: Matching the Tumor With Patient-Specific Goals to Inform Frontline Selection and Sequencing in Chronic Lymphocytic Leukemia
View More
Community Practice Connections™: MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes
View More
Community Practice Connections™: State-of-the-Art CMV Care: Experts’ Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections
View More
Cancer Summaries and Commentaries™: Report from New Orleans on the Latest Updates in GvHD Prevention and Treatment
View More
Community Practice Connections™: Maximizing Our Clinical Practices in Hodgkin Lymphoma: Integration of Recent Data Sets in Real World Settings
View More
Keeping Pace with Rapid Advancements in Multiple Myeloma Care
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
View More
Community Practice Connections™: Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy
View More
Oncology Roundtable: Treating MF and PV in 2023
View More
Community Practice Connections™: How We Do It: Application of State-of-the-Art MF and PV Care Today… With An Eye Toward How New Evidence and Combinations Will be Leveraged Tomorrow
View More
MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes
View More
7th Annual Live Medical Crossfire®: Hematologic Malignancies
07/22/2023
View More
Medical Crossfire®: How The Experts Treat Acute Lymphoblastic Leukemia: Case Discussions from Adolescent to Adult
View More
Cancer Summaries and Commentaries™: Report from New Orleans on the Latest Updates in the Treatment of MPNs
View More
Follicular Lymphoma Workshop: Forging Patient-Centric Plans with Targeted Therapies Across Lines of Care
View More
State-of-the-Art CMV Care: Experts’ Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections
View More
Updates from the Annual Hematology Meeting: Matching the Tumor with Patient Specific Goals to Inform Frontline Selection and Sequencing in Chronic Lymphocytic Leukemia
View More
Oncology Town Hall™: Primary Investigators Present Key Abstracts in the Management of CLL
View More
Bridging Clinical Gaps in Indolent and Aggressive B-Cell Lymphomas: The Investigators Demonstrate How Novel Mechanisms Will Impact Your Practice Tomorrow
View More
Medical Crossfire®: Experts Address Your Burning Questions on the Evolving Treatment of MF, PV, and ET!
View More
Burst CME: Regulatory Approval Pathways for Influenza Vaccines
View More
4th Annual Virtual Tumor Board®: Diagnosis and Management of Polycythemia Vera and Myelofibrosis
View More
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
Antibody-Drug Conjugates in Gynecological Cancer – Setting the Stage
View More
Coming Soon: Advances in Multiple Myeloma: Insights from Experts at the Moffit Cancer Center
December 14th 2022Melissa Alsina, MD, shares her excitement for an upcoming program wherein she and other key opinion leaders from the Moffit Cancer Center review updated data and optimal treatment strategies in the setting of multiple myeloma.
Elranatamab Produces Efficacy Response in Penta-or Triple-Class Refractory Multiple Myeloma
December 10th 2022Patients with penta-or triple-class refractory multiple myeloma who have not received prior B-cell maturation antigen therapy saw an improved objective response rate when elranatamab was given.
Daratumumab Combination Demonstrates Efficacy in Relapsed/Refractory Myeloma With EMD
November 30th 2022Among patients with extramedullary multiple myeloma, a regimen consisting of daratumumab plus dexamethasone, cyclophosphamide, etoposide, and cisplatin yielded a complete remission rate of 35.5% and an overall response rate of 67.7%.
Cilta-cel Produces Early Long-Lasting Responses in Pretreated Relapsed/Refractory Multiple Myeloma
November 28th 2022Data from the phase 2 CARTIFAN-1 study highlighted a favorable risk-benefit profile for a single infusion of ciltacabtagene autoleucel among patients with relapsed/refractory multiple myeloma.